Welcome to our dedicated page for Akoya Biosciences news (Ticker: AKYA), a resource for investors and traders seeking the latest updates and insights on Akoya Biosciences stock.
Akoya Biosciences, Inc. (AKYA), known as The Spatial Biology Company®, generates news that spans technology developments, collaborations, financial reporting, and corporate transactions. Company announcements emphasize its single-cell imaging and spatial proteomics platforms, which are used to phenotype cells with spatial context and study how they organize and interact in disease. News items often describe how Akoya’s PhenoCode™ Panels, PhenoCycler®, Phenor® Fusion, and Phenor HT instruments are applied across discovery, translational, and clinical research.
Investors and researchers following AKYA-related news will find updates on spatial biology and proteomics initiatives, including large-scale projects and partnerships. Recent releases highlight collaborations such as the Cancer Grand Challenges-funded study using PhenoCycler-Fusion, the SUPER study with the Singapore Translational Cancer Consortium leveraging the IO60 panel to investigate PD-1 immunotherapy response, and the Enable Medicine Pan-Cancer Atlas built on Akoya’s PhenoCycler-Fusion and IO60 technologies. These stories illustrate how Akoya’s platforms are integrated into biomarker discovery, drug development, and precision oncology efforts.
News coverage has also included financial results and operational updates, such as quarterly revenue composition, changes in operating expenses, and growth in the installed base of instruments and publications citing Akoya’s technology. In addition, corporate and capital markets news has been prominent, particularly the Amended and Restated Agreement and Plan of Merger with Quanterix Corporation and subsequent shareholder and activist responses to that transaction.
Following the completion of the merger on July 8, 2025, Akoya became a wholly owned subsidiary of Quanterix, and its common stock was removed from listing on Nasdaq. The AKYA news stream therefore serves as a historical archive of Akoya’s activities as an independent public company, covering its evolution in spatial biology, its collaborations, and the steps leading to its acquisition by Quanterix.
Akoya Biosciences (Nasdaq: AKYA) has partnered with Enable Medicine to launch the Enable Cloud Platform, designed to improve the analysis of high plex spatial imaging data from the PhenoCycler-Fusion system.
This end-to-end spatial cloud solution will be demonstrated at the AACR 2023 Annual Meeting in Orlando, Florida, from April 14-19, 2023. The platform is optimized for over 20,000 samples and aims to expedite the transition from data to insights.
Brian McKelligon, CEO of Akoya, noted that their R&D team has developed a proprietary algorithm that compresses data by 30-fold, enhancing partnerships and accelerating analysis. Enable Medicine's CEO, Sunil Bodapati, emphasized the platform's potential to improve clinical and research outcomes.
Akoya Biosciences (Nasdaq: AKYA) announced it will release its financial results for Q1 2023 on May 8, 2023, after market close. The management will hold a conference call at 5:00 p.m. ET to discuss the outcomes. Interested investors are advised to register for the call a day in advance. Akoya, known as The Spatial Biology Company®, specializes in spatial phenotyping solutions that enhance researchers' understanding of biology and human health. Their key products include PhenoCycler™, PhenoImager™ Fusion, and PhenoImager HT, which are aimed at various research needs.
Joe Driscoll retires after over four years as Chief Financial Officer of Akoya Biosciences (Nasdaq: AKYA), effective March 20, 2023. He will assist in the transition to new CFO Johnny Ek, who brings over 20 years of financial leadership from the diagnostics sector. Driscoll oversaw Akoya's financial performance during its IPO in April 2021. Brian McKelligon, CEO, praised Driscoll's contributions and welcomed Ek, highlighting his experience in driving growth. This leadership change aims to position Akoya for continued success in the spatial biology field.
Akoya Biosciences reported Q4 2022 revenue of $21.2 million, a 31% increase year-over-year, and a total revenue of $74.9 million for FY 2022, marking a 36% growth. The company anticipates FY 2023 revenue between $95 million and $98 million. Product revenue in Q4 was $15.7 million, reflecting a 22% rise. Akoya's gross profit for Q4 was $12.0 million with a margin of 57%. The installed base increased to 934 instruments by year-end. Significant advancements include partnerships in biopharma and an expanding product suite, enhanced by innovations presented at key industry conferences.
Akoya Biosciences (Nasdaq: AKYA) has appointed Jennifer Kamocsay as General Counsel, as announced on February 28, 2023. Kamocsay brings extensive legal expertise, having previously served as General Counsel at Rubius Therapeutics and Associate General Counsel at Progress Software Corporation. Her role will include overseeing all legal activities and providing strategic guidance to advance Akoya's spatial biology platform and partnerships. CEO Brian McKelligon expressed excitement about her joining, highlighting her potential contribution to the company’s growth in the discovery and clinical markets.
Akoya Biosciences, Inc. (Nasdaq: AKYA) will announce its financial results for Q4 and full year 2022 after market close on March 6, 2023. A conference call will follow at 5:00 p.m. ET for discussion. Interested investors must register online. CEO Brian McKelligon will also participate in the BTIG MedTech and Cowen Healthcare Conferences.
Akoya Biosciences (Nasdaq: AKYA) announces a breakthrough in spatial multiomics at the AGBT Annual Meeting, showcasing simultaneous detection of RNA and protein biomarkers across 23 tissue samples using their PhenoCycler-Fusion System. This innovative approach enhances understanding of tumor biology and enables researchers to uncover new biomarkers. The results will be presented during Akoya’s in-suite talk on February 7, further contributing to the field of genomics.
Akoya Biosciences, Inc. (Nasdaq: AKYA) announced its preliminary unaudited revenue for Q4 and the full year of 2022. Q4 revenue is projected between $20.7 million and $21.2 million, up from $16.2 million in Q4 2021. For the fiscal year 2022, revenue is expected to range from $74.3 million to $74.8 million, compared to $54.9 million in 2021. CEO Brian McKelligon emphasized the company's momentum and growing adoption of their spatial biology platforms.
Agilent Technologies (NYSE: A) has partnered with Akoya Biosciences (NASDAQ: AKYA) to commercialize end-to-end workflow solutions for tissue biomarker analysis in companion diagnostic development. This collaboration aims to create multiplex-immunohistochemistry diagnostic solutions, integrating Agilent's Dako Omnis autostaining instrument and Akoya's PhenoImager HT imaging platform. The partnership enhances clinical research capabilities for biopharma companies developing cancer therapeutics, enabling improved patient stratification and biomarker validation.
Akoya Biosciences (Nasdaq: AKYA) will participate in the 41st Annual J.P. Morgan Healthcare Conference on January 11, 2023, at 9:45 a.m. PT. CEO Brian McKelligon is set to present the company's advancements in spatial biology, particularly its single-cell imaging solutions that enhance the understanding of biology and health through spatial phenotyping. A webcast of the event will be available on Akoya's investor website. Akoya aims to serve researchers across various fields, offering key platforms such as PhenoCycler™ and PhenoImager™.
FAQ
What is the current stock price of Akoya Biosciences (AKYA)?
What is the market cap of Akoya Biosciences (AKYA)?
